Article
Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
The Pediatric infectious disease journal - 1 Aug 2011
Frange Pierre, Briand Nelly, Avettand-fenoel Véronique, Veber Florence, Moshous Despina, Mahlaoui Nizar, Rouzioux Christine, Blanche Stéphane, Chaix Marie-Laure
Abstract excerpt
BACKGROUND: Lopinavir/ritonavir (LPV/r) is now the protease inhibitor regimen of choice in the first-line antiretroviral therapy for children <6 years of age. METHODS: We included all the human immunodeficiency virus (HIV) type 1-infected highly active antiretroviral therapy (HAART)-naive children who started an LPV/r-based regimen between 2000 and 2009 at the Necker Hospital (Paris, France). Virologic failure...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.